<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD) is the most common form of <z:hpo ids='HP_0000726'>dementia</z:hpo> found in <z:hpo ids='HP_0000001'>all</z:hpo> human populations worldwide, while vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (VaD) is the second most common form of <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>New biomarkers for early and specific diagnosis of AD and VaD are needed to achieve greater insight into changes occurring in the brain and direct therapeutic strategies </plain></SENT>
<SENT sid="2" pm="."><plain>The objective of this explorative study was to discover candidate protein biomarkers for the differential diagnosis between VaD and AD </plain></SENT>
<SENT sid="3" pm="."><plain>Surface-enhanced laser desorption/ionization (SELDI) TOF-MS was used to differentially profile proteins and <z:chebi fb="7" ids="16670">peptides</z:chebi> in CSF samples from 28â€‰AD patients and 21 patients with VaD </plain></SENT>
<SENT sid="4" pm="."><plain>A combination of univariate (Kruskal-Wallis) and multivariate (independent component analysis) statistical approaches produced a list of 27 proteins and <z:chebi fb="7" ids="16670">peptides</z:chebi> that could differentiate between VaD and AD </plain></SENT>
<SENT sid="5" pm="."><plain>These markers represent various physiological processes, such as protein degradation (ubiquitin), protease inhibition (cystatin C and alpha-1-antichymoptrypsin), and <z:mp ids='MP_0001845'>inflammation</z:mp> (C3a and C4a) that are known to be represented in <z:hpo ids='HP_0002180'>neurodegenerative diseases</z:hpo> </plain></SENT>
</text></document>